Indication

Scleroderma

Scleroderma is a rare, chronic autoimmune connective tissue disorder characterized by microvascular dysfunction, immune dysregulation, and excessive extracellular matrix deposition leading to progressive fibrosis. Read more about Scleroderma

1 drugs 1 manufacturers

Drugs that treat it

Common Scleroderma therapies.

Showing 1–1 of 1 drugs

Sort

POTABA (potassium aminobenzoate)

PEYRONIE'S DISEASE·+4

GLENWOOD LAB.

Filter & compare in the drug finder →Opens the drug finder with Scleroderma preselected.

News & literature

Coming soon

Related codes

Coming soon

About Scleroderma.

It encompasses localized scleroderma, which primarily affects the skin and subcutaneous tissues, and systemic sclerosis, which involves extensive cutaneous thickening alongside internal organ complications affecting the lungs, heart, kidneys, and gastrointestinal tract.

Most commonly diagnosed in adults between 30 and 50 years of age with a marked female predominance, hallmark clinical features include Raynaud phenomenon, cutaneous sclerosis, telangiectasias, digital ulcers, and organ-specific fibrotic or vascular pathology.

nih.gov
Scleroderma is a rare, chronic autoimmune connective tissue disorder characterized by microvascular dysfunction, immune dysregulation, and excessive extracellular matrix deposition leading to progressive fibrosis It encompasses localized scleroderma, which primarily affects the skin and subcutaneous tissues, and systemic sclerosis, which involves extensive cutaneous thickening alongside internal organ complications affecting the lungs, heart, kidneys, and gastrointestinal tract
nih.gov
Scleroderma is a rare, chronic autoimmune connective tissue disorder characterized by microvascular dysfunction, immune dysregulation, and excessive extracellular matrix deposition leading to progressive fibrosis
nih.gov
Scleroderma is a rare, chronic autoimmune connective tissue disorder characterized by microvascular dysfunction, immune dysregulation, and excessive extracellular matrix deposition leading to progressive fibrosis Most commonly diagnosed in adults between 30 and 50 years of age with a marked female predominance, hallmark clinical features include Raynaud phenomenon, cutaneous sclerosis, telangiectasias, digital ulcers, and organ-specific fibrotic or vascular pathology
medlineplus.gov
It encompasses localized scleroderma, which primarily affects the skin and subcutaneous tissues, and systemic sclerosis, which involves extensive cutaneous thickening alongside internal organ complications affecting the lungs, heart, kidneys, and gastrointestinal tract Most commonly diagnosed in adults between 30 and 50 years of age with a marked female predominance, hallmark clinical features include Raynaud phenomenon, cutaneous sclerosis, telangiectasias, digital ulcers, and organ-specific fi...
nih.gov
Most commonly diagnosed in adults between 30 and 50 years of age with a marked female predominance, hallmark clinical features include Raynaud phenomenon, cutaneous sclerosis, telangiectasias, digital ulcers, and organ-specific fibrotic or vascular pathology
nih.gov
Most commonly diagnosed in adults between 30 and 50 years of age with a marked female predominance, hallmark clinical features include Raynaud phenomenon, cutaneous sclerosis, telangiectasias, digital ulcers, and organ-specific fibrotic or vascular pathology

Personalize your experience

Follow Scleroderma and get updates as they land.

Create a free account

Already a member? Sign in

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it